Skip to main content

Table 2 Association between RBM3 expression and clinicopathological parameters

From: Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study

  RBM3 staining intensity
  0-2 3  
n(%) 95 (44.2) 120 (55.8) p-value
Age    
Mean 68.00 67.15 0.673
(range) (47-83) (46-81)  
Gender    
Female 45(47.4) 63(52.5) 0.457
Male 50(52.6) 57(47.5)  
Clark level    
II 21(22.3) 50(42.4) 0.005**
IIII 48(51.1) 46(39.0)  
IV-V 25(26.6) 22(18.6)  
missing 1 2  
Breslow(mm)    
Mean 2.47 1.12 0.001**
(range) (0.08-40.00) (0.11-7.00)  
Ulceration    
No 71(74.7) 109(91.6) 0.001**
Yes 24(25.3) 10(8.4)  
missing 0 1  
Lymphocytic    
infiltrate    
0-1 26(27.4) 34(28.6) 0.846
2-3 69(72.6) 85(71.4)  
missing 0 1  
Clinical stage    
I 54(76.1) 95(91.3) 0.005*
II-IV 17(23.9) 9(8.7)  
missing 24 16  
Vascular invasion    
No 87(91.6) 114(95.0) 0.314
Yes 8(8.4) 6(5.0)  
Localization    
Head and neck 15(16.0) 16(14.0) 0.352
Extremities 40(42.6) 59(51.8)  
Frontal thorax 10(10.6) 15(13.2)  
Dorsal thorax 29(30.9) 24(21.1)  
missing 1 6  
Type    
SSM, LMM, Other 65(58.9) 97(68.9) 0.027*
NMM 30(31.6) 22(18.5)  
missing 0 1  
Mitotic count    
< 1/mm2 34(35.8) 71(59.2) 0.001**
> = 1/mm2 61(64.2) 49(40.8)  
  1. *Significant at the 0.05 level
  2. ** Significant at the 0.01 level
  3. § Mann Whitney U test for comparison of means
  4. SSM = Superficial spreading melanoma
  5. NMM = Nodular malignant melanoma
  6. LMM = Lentigo malignant melanoma